Wall Street analyst estimates for Acurx Pharmaceuticals, Inc. (ACXP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.45 | ||
| 2026-08-14 | $-0.53 | $-0.38 | -40.7% |
| 2026-05-12 | $-0.62 | $-0.59 | -5.1% |
| 2026-03-13 | $-0.31 | $-1.01 | +69.3% |
| 2025-11-12 | $-1.23 | $-1.61 | +23.6% |
| 2025-08-12 | $-1.89 | $-2.00 | +5.5% |
| 2025-05-13 | $-2.20 | $-0.14 | -1471.4% |
| 2025-03-18 | $-3.20 | $-0.18 | -1677.8% |
Valuation Ratios
| Price / Book | 0.73 |
| EV / EBITDA | 0.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B |
| Selling, General & Admin | $2.4M | $2.4M | $10.8M | $7.3M | $8.5M | $8.7M | $6.26B |
| Operating Expenses | $5.9M | $4.6M | $12.8M | $12.1M | $14.6M | $14.1M | $8.1M |
| Operating Income | -$5.9M | -$4.6M | -$12.8M | -$12.1M | -$14.6M | -$14.1M | -$8.1M |
| EBITDA | 0 | 0 | -$12.7M | -$12.1M | -$14.6M | 0 | -$8.0M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| EPS | $-12.00 | $-9.28 | $-24.96 | $-22.36 | $-23.01 | $-17.59 | $-5.32 |
| EPS (Diluted) | $-12.00 | $-9.28 | $-24.96 | $-22.36 | $-23.01 | $-17.59 | $-5.32 |
| Shares Outstanding (Diluted) | $477050 | $495800 | $510800 | $540800 | $633600 | $851550 | $1.5M |
Price
| Price | $1.38 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADIL · APRE · APVO · BCDA · BCLI · CELZ · GLTO
Explore sector: Healthcare · Biotechnology
More sections of ACXP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks